Vav1: a key signal transducer downstream of the TCR

被引:97
作者
Tybulewicz, VLJ
Ardouin, L
Prisco, A
Reynolds, LF
机构
[1] Natl Inst Med Res, Div Immune Cell Biol, London NW7 1AA, England
[2] Ctr Immunol Marseille Luminy, Marseille, France
[3] CNR, Inst Genet & Biophys, I-80125 Naples, Italy
关键词
D O I
10.1034/j.1600-065X.2003.00032.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Vav1 is a 95-kDa protein expressed in all hemopoietic cells that becomes rapidly tyrosine phosphorylated following T cell antigen receptor (TCR) stimulation. Vav1 contains multiple domains characteristic of signal transducing proteins, including a Dbl homology domain, a hallmark of a guanine nucleotide exchange factor (GEF) for Rho-family GTPases. Indeed Vav1 is a GEF for Rac1, Rac2 and RhoG, and it is activated following tyrosine phosphorylation. Generation of mice deficient in Vav1 has shown that it plays an important role in selection events within the thymus, including both positive and negative selection, consistent with Vav1 transducing TCR signals required to drive these processes. Furthermore, Vav1-deficient T cells are defective in TCR-induced proliferation and cytokine synthesis. Analysis of TCR signaling pathways in Vav1-deficient T cells and thymocytes has shown that Vav1 is required to transduce signals to the activation of a calcium flux, extracellular signal-regulated kinase (ERK) and the nuclear factor kappaB (NF-kappaB) transcription factor. Vav1 has also been shown to control the activation of phospholipase Cgamma1 (PLCgamma1) via both phosphoinositide-3-kinase (PI3K)-dependent and -independent pathways. Finally, Vav1 has been shown to transduce TCR signals to some but not all cytoskeleton-dependent pathways. In particular, Vav1 is required for efficient TCR-induced conjugate formation with antigen presenting cells (APCs), activation of the integrin leukocyte function-associated antigen-1 (LFA-1) and cell polarization.
引用
收藏
页码:42 / 52
页数:11
相关论文
共 97 条
[41]  
Hobert O, 1996, ONCOGENE, V12, P1577
[42]  
HOBERT O, 1994, J BIOL CHEM, V269, P20225
[43]   Defects in actin-cap formation in Vav-deficient mice implicate an actin requirement for lymphocyte signal transduction [J].
Holsinger, LJ ;
Graef, IA ;
Swat, W ;
Chi, T ;
Bautista, DM ;
Davidson, L ;
Lewis, RS ;
Alt, FW ;
Crabtree, GR .
CURRENT BIOLOGY, 1998, 8 (10) :563-572
[44]   Vav3 modulates B cell receptor responses by regulating phosphoinositide 3-kinase activation [J].
Inabe, K ;
Ishiai, M ;
Scharenberg, AM ;
Freshney, N ;
Downward, J ;
Kurosaki, T .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (02) :189-200
[45]   Maintaining the norm: T-CELL homeostasis [J].
Jameson, SC .
NATURE REVIEWS IMMUNOLOGY, 2002, 2 (08) :547-556
[46]   LOSS OF THE AMINO-TERMINAL HELIX-LOOP-HELIX DOMAIN OF THE VAV PROTOONCOGENE ACTIVATES ITS TRANSFORMING POTENTIAL [J].
KATZAV, S ;
CLEVELAND, JL ;
HESLOP, HE ;
PULIDO, D .
MOLECULAR AND CELLULAR BIOLOGY, 1991, 11 (04) :1912-1920
[47]  
KATZAV S, 1994, J BIOL CHEM, V269, P32579
[48]   VAV, A NOVEL HUMAN ONCOGENE DERIVED FROM A LOCUS UBIQUITOUSLY EXPRESSED IN HEMATOPOIETIC-CELLS [J].
KATZAV, S ;
MARTINZANCA, D ;
BARBACID, M .
EMBO JOURNAL, 1989, 8 (08) :2283-2290
[49]  
KIENER PA, 1993, J BIOL CHEM, V268, P24442
[50]   Vav regulates peptide-specific apoptosis in thymocytes [J].
Kong, YY ;
Fischer, KD ;
Bachmann, MF ;
Mariathasan, S ;
Kozieradzki, I ;
Nghiem, MP ;
Bouchard, D ;
Bernstein, A ;
Ohashi, PS ;
Penninger, JM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (11) :2099-2111